John Leonard, CFA
Special situations, micro-cap, contrarian, CFA

Investors Are Overlooking The Significant Upside In Actinium Pharmaceuticals

Actinium Pharmaceuticals (NYSEMKT:ATNM) is a cancer-focused biotech that is fundamentally misunderstood due to a perfect storm of "valuation limiting" factors that provide a classic low risk/high reward investment opportunity. The current valuation does not accurately reflect the significant potential licensing opportunities or attractiveness to a larger acquirer given the current M&A environment.

Company overview

ATNM focuses on the development of cancer drugs based on its proprietary Alpha Particle Immunotherapy platform, which is potentially applicable to a wide variety of cancers. This is a highly potent and selective form of targeted radiotherapy, in which powerful alpha emitting radioisotopes (Actinium 225* or Bismuth 213) are carried by monoclonal antibodies (mAbs) directly to cancer cells.

ATNM has two clinical stage drugs:...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details